|
| Status |
Public on Dec 07, 2020 |
| Title |
AB20_AB1_Day2_NR |
| Sample type |
SRA |
| |
|
| Source name |
AB1 tumour
|
| Organism |
Mus musculus |
| Characteristics |
tissue: AB1 tumour
age: 8-10 weeks
gender: f
treatment: aCTLA-4 + aPDL1
group: NR
strain: balb/c
timepoint: d2
|
| Treatment protocol |
100ug anti-CTLA-4 + anti-PDL1 given i.p., follwed by 100ug anti-PDL1 i.p. given 2 and 4 days later *Note some samples were collected before treatment
|
| Growth protocol |
Subcutaneous tumour growth
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Frozen tumour dissociation with Trizol followed by chloroform extraction and purification using RNeasy MinElute
Illumina 50bp single-end sequencing
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina HiSeq 2000 |
| |
|
| Description |
AB20
|
| Data processing |
read alignment with Kallisto
count quantification with tximport
Genome_build: GRCm38.p6
Supplementary_files_format_and_content: txt files in compressed gz format
|
| |
|
| Submission date |
Jul 07, 2020 |
| Last update date |
Dec 07, 2020 |
| Contact name |
Wee Loong Chin |
| Organization name |
National Centre For Asbestos Related Diseases
|
| Street address |
Level 5, Qq Block, Qeii Medical Centre 6 Verdun St, Nedlands
|
| City |
Perth |
| ZIP/Postal code |
6009 |
| Country |
Australia |
| |
|
| Platform ID |
GPL13112 |
| Series (2) |
| GSE153941 |
Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer [bulk RNA-seq] |
| GSE153943 |
Dynamic IFNβ signalling underlies treatment response to immune checkpoint therapy in cancer |
|
| Relations |
| BioSample |
SAMN15464635 |
| SRA |
SRX8679985 |
